Agenus Inc.(AGEN)

Biotechnology · Lexington, MA

$8.42-0.32 (-3.61%)

Delayed quote: Oct 6, 2026, 9:40 AM EDT

About Agenus Inc.

Agenus Inc. is a clinical-stage biotechnology firm operating globally, dedicated to the discovery and development of immuno-oncology therapies. The company's innovative technological arsenal includes Retrocyte Display, a sophisticated antibody expression platform designed to identify fully human and humanized monoclonal antibodies, alongside other proprietary display technologies. Agenus is also actively involved in vaccine development programs, featuring the Prophage vaccine candidate and QS-21 Stimulon, a widely recognized saponin-based vaccine adjuvant. Its robust and diverse pipeline of therapeutic candidates targets various immune checkpoints and cancer pathways. Notable assets in clinical development include: Balstilimab: An anti-PD-1 antagonist that has successfully completed Phase II trials for the treatment of second-line cervical cancer. AGEN1181: A monospecific anti-CTLA-4 antibody currently undergoing Phase 1/2 clinical evaluation. AGEN2373: An anti-CD137 monospecific antibody in Phase 1 clinical trials. AGEN1423: A bi-functional anti-CD73/TGFß TRAP antibody, engineered to modulate the tumor microenvironment, which has concluded Phase 1 studies. AGEN1777: An anti-TIGIT bispecific antibody. AGEN1327: A human monoclonal antibody. INCAGN1876: An anti-GITR monospecific antibody. INCAGN1949: An anti-OX40 monospecific antibody. INCAGN2390: An anti-TIM-3 monospecific antibody. INCAGN2385: An anti-LAG-3 monospecific antibody. MK-4830: A monospecific antibody engineered to target ILT4. AGENT 797: An iNKT cell therapy, currently in Phase 1 for solid tumors, multiple myeloma, and viral ARDS, with ongoing clinical investigation for hematological malignancies and multiple myeloma/B cell indications. AGEN1884: A first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. utilizes a portfolio of trademarks, including ASV, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon, alongside its own company name. Strategic alliances are maintained with partners such as Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. Established in 1994, the company originally operated as Antigenics Inc. before rebranding to Agenus Inc. in January 2011. Its corporate headquarters are situated in Lexington, Massachusetts.

Lexington, MA

81 employees

www.agenusbio.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Garo H. Armen

View full financials

NAME

MARKET CAP

EV/FCF RATIO

TTM

Agenus Inc. (AGEN)

$350.42M

N/A

Embecta Corp. (EMBC)vs ›

$348.25M

9.93x

9.65x

69.46x

48.92x

ClearPoint Neuro, Inc. (CLPT)vs ›

$349.38M

N/A

Artiva Biotherapeutics, Inc. (ARTV)vs ›

$342.23M

N/A

Cabaletta Bio, Inc. (CABA)vs ›

$336.71M

N/A

C4 Therapeutics, Inc. (CCCC)vs ›

$331.70M

N/A

Opus Genetics, Inc. (IRD)vs ›

$360.81M

N/A

Enanta Pharmaceuticals, Inc. (ENTA)vs ›

$365.81M

N/A

50.02x

37.43x

35.40x

Fennec Pharmaceuticals Inc. (FENC)vs ›

$369.85M

N/A

6.23x

CapsoVision, Inc. (CV)vs ›

$321.27M

N/A

DATE

EV/FCF RATIO

2013-05-10

2399.50x

2013-05-09

2372.35x

2013-05-08

2404.93x

2013-05-07

2231.18x

2013-05-06

2383.21x

2013-05-03

2448.37x

2013-05-02

2388.64x

2013-05-01

2611.26x

2013-04-30

2654.69x

2013-04-29

2692.70x

2013-04-26

2529.81x

2013-04-25

2540.67x

2013-04-24

2502.66x

2013-04-23

2513.52x

2013-04-22

2388.64x

2013-04-19

2350.63x

2013-04-18

2237.15x

2013-04-17

2328.91x

2013-04-16

2437.51x

2013-04-15

2437.51x

2013-04-12

2464.66x

2013-04-11

2556.96x

2013-04-10

2491.80x

2013-04-09

2280.05x

2013-04-08

2247.47x

2013-04-05

2095.44x

2013-04-04

2138.88x

2013-04-03

2095.44x

2013-04-02

2171.46x

2013-04-01

2100.87x

2013-03-28

2128.02x

2013-03-27

2176.89x

2013-03-26

2176.89x

2013-03-25

2187.74x

2013-03-22

2144.31x

2013-03-21

2171.46x

2013-03-20

2269.19x

2013-03-19

2274.62x

2013-03-18

242025.75x

2013-03-15

250032.44x

2013-03-14

252320.07x

2013-03-13

252320.07x

2013-03-12

251176.26x

2013-03-11

254607.70x

2013-03-08

253463.89x

2013-03-07

256895.33x

2013-03-06

255751.51x

2013-03-05

256323.42x

2013-03-04

252891.98x

2013-03-01

247172.91x

2013-02-28

246029.09x

2013-02-27

236306.68x

2013-02-26

239738.12x

2013-02-25

236306.68x

2013-02-22

250032.44x

2013-02-21

244885.28x

2013-02-20

248316.72x

2013-02-19

262042.49x

2013-02-15

250604.35x

2013-02-14

251176.26x

2013-02-13

250032.44x

2013-02-12

260898.68x

2013-02-11

271193.00x

2013-02-08

270049.19x

2013-02-07

280343.51x

2013-02-06

279199.70x

2013-02-05

264902.02x

2013-02-04

257467.23x

2013-02-01

263186.30x

2013-01-31

261470.58x

2013-01-30

250604.35x

2013-01-29

251748.16x

2013-01-28

250032.44x

2013-01-25

239738.12x

2013-01-24

241453.84x

2013-01-23

249460.54x

2013-01-22

243169.56x

2013-01-18

238022.40x

2013-01-17

235734.77x

2013-01-16

233447.14x

2013-01-15

234590.96x

2013-01-14

232303.33x

2013-01-11

231159.51x

2013-01-10

235162.86x

2013-01-09

229443.79x

2013-01-08

235162.86x

2013-01-07

236878.58x

2013-01-04

240310.03x

2013-01-03

238594.30x

2013-01-02

243741.47x

2012-12-31

235734.77x

2012-12-28

214002.31x

2012-12-27

217433.75x

2012-12-26

220293.28x

2012-12-24

220293.28x

2012-12-21

224868.54x

2012-12-20

223152.82x

2012-12-19

226584.26x

2012-12-18

232303.33x

2012-12-17

227728.07x

2012-12-14

224868.54x

2012-12-13

223152.82x

2012-12-12

223181.41x

2012-12-11

230015.70x

2012-12-10

230015.70x

2012-12-07

239166.21x

2012-12-06

249460.54x

2012-12-05

244885.28x

2012-12-04

247172.91x

2012-12-03

240881.93x

2012-11-30

248888.63x

2012-11-29

237450.49x

2012-11-28

224296.63x

2012-11-27

219149.47x

2012-11-26

209998.96x

2012-11-23

212286.58x

2012-11-21

208283.24x

2012-11-20

209427.05x

2012-11-19

206567.52x

2012-11-16

202564.17x

2012-11-15

198560.82x

2012-11-14

206567.52x

2012-11-13

212286.58x

2012-11-12

228299.98x

2012-11-09

240310.03x

2012-11-08

244313.37x

2012-11-07

7314.01x

2012-11-06

7611.78x

2012-11-05

7562.16x

2012-11-02

7429.81x

2012-11-01

7446.36x

2012-10-31

7429.81x

2012-10-26

7347.10x

2012-10-25

7727.58x

2012-10-24

7363.64x

2012-10-23

7347.10x

2012-10-22

7363.64x

2012-10-19

7347.10x

2012-10-18

7694.50x

2012-10-17

7826.84x

2012-10-16

7711.04x

2012-10-15

7694.50x

2012-10-12

7611.78x

2012-10-11

7909.56x

2012-10-10

7677.96x

2012-10-09

7843.39x

2012-10-08

7959.19x

2012-10-05

7810.30x

2012-10-04

7711.04x

2012-10-03

7744.13x

2012-10-02

7677.96x

2012-10-01

7595.24x

2012-09-28

7661.41x

2012-09-27

7644.87x

2012-09-26

7578.70x

2012-09-25

7942.64x

2012-09-24

7893.01x

2012-09-21

7777.21x

2012-09-20

7462.90x

2012-09-19

7495.98x

2012-09-18

7462.90x

2012-09-17

7479.44x

2012-09-14

7562.16x

2012-09-13

8108.07x

2012-09-12

8273.50x

2012-09-11

8372.76x

2012-09-10

8323.13x

2012-09-07

8306.59x

2012-09-06

8240.42x

2012-09-05

7959.19x

2012-09-04

7793.76x

2012-08-31

7628.33x

2012-08-30

7826.84x

2012-08-29

7893.01x

2012-08-28

7711.04x

2012-08-27

7413.27x

2012-08-24

7793.76x

2012-08-23

7644.87x

2012-08-22

7611.78x

2012-08-21

7545.61x

2012-08-20

7727.58x

2012-08-17

7942.64x

2012-08-16

7859.93x

2012-08-15

7562.16x

2012-08-14

7462.90x

2012-08-13

7462.90x

2012-08-10

7181.67x

2012-08-09

7644.87x

EV/FCF Ratio: N/A

AGEN EV/FCF Ratio Chart

AGEN EV/FCF Ratio Metrics

AGEN Competitors' EV/FCF Ratio

Cash Flow Valuation Comparison

EV/FCF Ratio Formula & Definition

AGEN EV/FCF Ratio History

Related Metrics